scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, March 19, 2025

Management to host conference call and webcast, after-market on March 19, 2025, at 4:30 p.m. ET

BURLINGTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, March 19, 2025, to discuss the financial results for the fourth quarter and full year 2024, and provide a business update.

Registration and access for the conference call can be completed through this direct registration link.

The live webcast and replay of the conference call can be accessed here or under “News & Events” in the Investor Relations section of the Company’s website, www.scpharmaceuticals.com.

About scPharmaceuticals

At scPharmaceuticals, we are powered by passion, driven by patient care. Our Mission is focused on advancing cardiorenal care through innovative, integrated treatments that address unmet patient needs.

Our goal is to become the foremost advocate for patient-centric cardiorenal care, driving global health improvements through specialized, multidisciplinary approaches. scPharmaceuticals is expanding its reach, offering integrated therapies and products that address diverse healthcare needs and potentially improve the lives of our patients. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit www.scPharmaceuticals.com.

Katherine Miranda
scPharmaceuticals Inc., 781-301-6869
[email protected]

Investors:
Nick Colangelo
Gilmartin Group, 339-225-1047
[email protected]



Xenon to Present at Stifel 2025 Virtual CNS Forum

VANCOUVER, British Columbia and BOSTON, March 12, 2025 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the Stifel 2025 Virtual CNS Forum taking place from March 18-19, 2025.

Fireside Chat Presentation Details:

Date: Wednesday, March 19, 2025
   
Time: 12:00-12:25 PM Eastern Time
   
Webcast: Register here
   
Presenter: Dr. Chris Kenney, Chief Medical Officer
   

A live audio webcast of the company presentation will be available on the “Investors” section of Xenon’s website and posted for replay following the event. The above listed dates and times are subject to change.


About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit www.xenon-pharma.com.

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Contacts:

For Investors:

Chad Fugere
Vice President, Investor Relations
(857) 675-7275
[email protected]

For Media:

Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
[email protected]



Kalaris and AlloVir Announce Stockholder Approval of Merger

Combined company expected to trade on Nasdaq under “KLRS” after closing

PALO ALTO, Calif. and LEXINGTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) — Kalaris Therapeutics, Inc. (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent diseases of the retina, and AlloVir, Inc. (Nasdaq: ALVR) announced today the results for the proposals voted upon by AlloVir stockholders at a Special Meeting of Stockholders held on March 12, 2025. The AlloVir stockholders voted in favor of all proposals at the Special Meeting, including to approve the proposed merger between the companies.

The closing of the merger is expected to occur as soon as practicable, subject to the satisfaction or waiver of the remaining customary closing conditions. Following the closing of the merger, the combined company is expected to be renamed Kalaris Therapeutics, Inc. and trade on The Nasdaq Capital Market under the ticker “KLRS.”

About Kalaris

Kalaris is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases. The company is focused on development of TH103, a novel, differentiated anti-VEGF investigational therapy. Developed by Dr. Napoleone Ferrara, TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is currently being evaluated in an ongoing, Phase 1 clinical trial for the treatment of neovascular Age-related Macular Degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as Diabetic Macular Edema (DME), and Retinal Vein Occlusion (RVO).

About AlloVir

AlloVir is an allogeneic T cell immunotherapy company that was focused on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 concerning AlloVir, Kalaris, the proposed merger and other matters. All statements other than statements of historical fact contained in this press release are forward-looking statements. These forward-looking statements are made as of the date they were first made, and were based on the then-current expectations, estimates, forecasts, and projections, as well as the beliefs and assumptions of management. There can be no assurance that future developments affecting AlloVir, Kalaris or the proposed merger will be those that have been anticipated.

Forward-looking statements are subject to a number of important risks and uncertainties, many of which involve factors or circumstances that are beyond AlloVir’s and Kalaris’ control. Actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to (i) the risk that the conditions to the closing of the proposed merger are not satisfied; (ii) uncertainties as to the timing of the consummation of the proposed merger and the ability of each of AlloVir and Kalaris to consummate the proposed merger; (iii) risks related to AlloVir’s continued listing on Nasdaq until closing of the proposed merger; (iv) risks related to AlloVir’s and Kalaris’ ability to manage their operating expenses and their expenses associated with the proposed merger pending the closing, as well as uncertainties regarding the impact any delay in the closing would have on the anticipated cash resources of the combined company upon closing and other events and unanticipated spending and costs that could reduce the combined company’s cash resources; (v) the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the merger agreement; (vi) risks related to the failure or delay in obtaining required approvals from any governmental or quasi-governmental entity necessary to consummate the proposed merger; (vii) the risk that as a result of adjustments to the exchange ratio, AlloVir stockholders and Kalaris stockholders could own more or less of the combined company than is currently anticipated; (viii) risks related to the market price of AlloVir’s common stock relative to the value suggested by the exchange ratio; (ix) unexpected costs, charges or expenses resulting from the proposed merger; (x) competitive responses to the proposed merger; (xi) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed merger; (xii) the uncertainties associated with Kalaris’ product candidates, as well as risks associated with the clinical development and regulatory approval of product candidates, including potential delays in the completion of clinical trials; (xiii) risks related to the inability of the combined company to obtain sufficient additional capital to continue to advance these product candidates; (xiv) uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; (xv) risks related to the failure to realize any value from product candidates being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; (xvi) the ability to obtain, maintain, and protect intellectual property rights related to product candidates; (xvii) changes in regulatory requirements and government incentives; (xviii) competition; (xix) risks associated with the possible failure to realize, or that it may take longer to realize than expected, certain anticipated benefits of the proposed merger, including with respect to future financial and operating results; and (xx) the risk of involvement in any current or future litigation, including securities class action litigation, that could divert the attention of the management of AlloVir or the combined company, harm the combined company’s business and may not be sufficient for insurance coverage to cover all costs and damages, among others. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. These and other risks and uncertainties are more fully described in periodic filings with the SEC, including the factors described in the section titled “Risk Factors” in AlloVir’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (the “SEC”), the final prospectus on Form 424(b)(3) filed with the SEC on February 10, 2025 and in other filings that AlloVir makes and will make with the SEC. You should not place undue reliance on these forward-looking statements, which are made only as of the date hereof or as of the dates indicated in the forward-looking statements. Each of AlloVir and Kalaris expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based, except as required by law. This press release does not purport to summarize all of the conditions, risks and other attributes of an investment in AlloVir or Kalaris.

Kalaris Therapeutics Investor
Contact: 
Corey Davis, Ph.D. 
LifeSci Advisors 
+1 212 915 2577 
[email protected] 

AlloVir Media and Investor Contact:

[email protected]



McGrath to Participate in the Sidoti Small-Cap Virtual Conference

McGrath to Participate in the Sidoti Small-Cap Virtual Conference

LIVERMORE, Calif.–(BUSINESS WIRE)–McGrath RentCorp (“McGrath” or the “Company”) (Nasdaq: MGRC), a leading business-to-business rental company in North America, today announced that Joe Hanna, Chief Executive Officer, and Keith Pratt, EVP, and Chief Financial Officer, will participate in investor meetings at the Sidoti Small-Cap Virtual Conference on Wednesday, March 19, 2025.

ABOUT MCGRATH:

McGrath RentCorp (Nasdaq: MGRC) is a leading business-to-business rental company in North America with a strong record of profitable business growth. Founded in 1979, McGrath’s operations are centered on modular solutions through its Mobile Modular and Mobile Modular Portable Storage businesses. In addition, its TRS-RenTelcobusiness offers electronic test equipment rental solutions. The Company’s rental product offerings and services are part of the circular supply economy, helping customers work more efficiently, and sustainably manage their environmental footprint. With over 40 years of experience, McGrath’s success is driven by a focus on exceptional customer experiences. This focus has underpinned the Company’s long-term financial success and supported over 30 consecutive years of annual dividend increases to shareholders, a rare distinction among publicly listed companies.

Headquartered in Livermore, California. Additional information about McGrath and its businesses is available at mgrc.com and investors.mgrc.com.

Keith E. Pratt

EVP & Chief Financial Officer

925-606-9200

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Automotive Manufacturing Aerospace Manufacturing Telecommunications Other Construction & Property Architecture Technology Commercial Building & Real Estate Construction & Property Mining/Minerals Utilities Oil/Gas Agriculture Natural Resources Energy Other Manufacturing Machinery Machine Tools, Metalworking & Metallurgy

MEDIA:

Logo
Logo

Lowey Dannenberg Notifies Neumora Therapeutics, Inc. (“Neumora” or the “Company”) (NASDAQ: NMRA) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm

NEW YORK, March 12, 2025 (GLOBE NEWSWIRE) — Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Neumora Therapeutics, Inc. (“Neumora” or the “Company”) (NASDAQ: NMRA) for violations of the federal securities laws on behalf of investors who purchased or acquired Neumora common stock at the time of the Company’s Initial Public Offering (“IPO”) on September 15, 2023.

On February 7, 2025, a complaint was filed against the Company, certain of its current officers and directors, and underwriters, alleging that in connection with its IPO, Defendants made false and/or misleading statements and/or failed to disclose that: (i) in order for Neumora to justify conducting its Phase Three Program, Neumora was forced to amend BlackThorn’s original Phase Two Trial inclusion criteria to include a patient population with moderate to severe major depressive disorder (“MDD”) to show that Navacaprant offered a statistically significant improvement in treating MDD; (ii) and to that same end, Neumora also added a prespecified analysis to the Phase Two statistical analysis plan, focusing on patients suffering from moderate to severe MDD; and (iii) the Phase Two Trials lacked adequate data, particularly in regards to the patient population size and the ratio of male to female patients within the patient population, to be able to accurately predict the results of the KOASTAL-1 study.

When investors learned the truth, Neumora’s common stock declined precipitously, injuring investors.

If you suffered a loss of more than $100,000 in Neumora’s securities, and wish to participate, or learn more, click here, or please contact our attorneys at (914) 733-7256 or via email to Andrea Farah ([email protected]) or Vincent R. Cappucci Jr. ([email protected]).

Any investor who wishes to serve as Lead Plaintiff must act before April 7, 2025.

About Lowey Dannenberg

Lowey Dannenberg is a national firm representing institutional and individual investors, who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has recovered billions of dollars on behalf of its clients.

Contact:
Lowey Dannenberg P.C.
44 South Broadway, Suite 1100
White Plains, NY 10601
Tel: (914) 733-7234
Email: [email protected]

SOURCE: Lowey Dannenberg P.C.



Dyadic to Report 2024 Full Year Financial Results and Host Conference call on Wednesday, March 26, 2025

JUPITER, Fla., March 12, 2025 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications, today announced that it will report its financial results for the year ended 2024 and host a corporate update conference call on Wednesday, March 26, 2025.

Conference Call Information

Date: Wednesday, March 26, 2025

Time: 5:00 p.m. Eastern Time

Dial-in numbers: Toll Free: +1-877-407-0784; International +1-201-689-8560

Conference ID: 13751386

Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1705988&tp_key=509eb4b293. An archive of the webcast will be available within 24 hours after completion of the live event and will be accessible on the Investor Relations section of the Company’s website at www.dyadic.com. To access the replay of the webcast, please follow the webcast link above.

If you have any questions that you would like to ask management during the Q&A session, please email [email protected] prior to the conference call. 

About Dyadic International, Inc.
Dyadic International, Inc., is a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness.

Dyadic’s microbial gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Our lead platform, the C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is currently used to speed development, lower production costs, and potentially improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. Dyadic has also developed the DapibusTM protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, such as food, nutrition, and wellness.

Dyadic is focusing on leveraging its microbial platform technologies for itself and its collaborators in a wide range of applications, including human and animal vaccines, therapeutics, food, nutrition, wellness, and internal biological products.

For more information about Dyadic International, visit www.dyadic.com.

Safe Harbor Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding Dyadic International’s expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, such as the success of our clinical trial and interest in our protein production platforms, our research projects and third-party collaborations, as well as the availability of necessary funding. Actual events or results may differ materially from those in the forward-looking statements because of various important factors, including those described in the Company’s most recent filings with the SEC. Dyadic assumes no obligation to update publicly any such forward-looking statements, whether because of new information, future events or otherwise. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled “Risk Factors” in Dyadic’s annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic’s periodic filings with the SEC, which are accessible on the SEC’s website and at www.dyadic.com.

Contact:
Dyadic International, Inc.
Ping W. Rawson
Chief Financial Officer
Phone: (561) 743-8333
Email: [email protected]



Harvard Bioscience, Inc. to Participate in Two Investor Conferences in March 2025

HOLLISTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) — Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will participate in two investor conferences in March 2025:

  • The 37th Annual Roth Conference is being held on March 16-18, 2025, at the Laguna Cliffs Marriott Resort in Dana Point, CA. On March 17th, management will host one-on-one meetings and is scheduled for a Fireside Chat on the same day starting at 10 a.m. PT (1:00 p.m. ET). The live webcast is available on HBIO’s website at https://investor.harvardbioscience.com/events-and-presentations. Investors interested in scheduling a one-on-one meeting can contact [email protected].
  • The KeyBanc Capital Markets Healthcare Forum is a virtual event scheduled for March 19, 2025. Management will host one-on-one meetings and is also scheduled for a Fireside Chat with Paul Knight, KeyBanc Capital Markets, on the same day starting at 3:45 p.m. ET. The live webcast is available on HBIO’s website at https://investor.harvardbioscience.com/events-and-presentations. Investors interested in scheduling a one-on-one meeting can contact [email protected].

About Harvard Bioscience, Inc.

Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in North America, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world. For more information, please visit our website at www.harvardbioscience.com 

Company Contact: 
Harvard Bioscience 
Jennifer Cote, Chief Financial Officer 
(508) 893-3120 

Investor Contacts: 
Three Part Advisors 
Sandy Martin / Erol Girgin
[email protected] 
(214) 616-2207 



Great Lakes Dredge & Dock to Present at Sidoti Small Cap Virtual Conference on Wednesday, March 19, 2025

HOUSTON, March 12, 2025 (GLOBE NEWSWIRE) — Great Lakes Dredge & Dock Corporation (“Great Lakes” or the “Company”) (NASDAQ: GLDD), the largest provider of dredging services in the United States, announced today that its Senior Vice President and Chief Financial Officer, Scott Kornblau, will be presenting and hosting one-on-one meetings with investors at the Sidoti Small Cap Virtual Conference on Wednesday, March 19, 2025.

The presentation will begin at 10:00 AM ET on Wednesday, March 19, 2025, and can be accessed live at https://sidoti.zoom.us/webinar/register/WN_6f1nnGA6Qny8PEA9ztGJ5w.

To access the webcast and supporting material, please visit the investor relations section of the GLDD website at https://investor.GLDD.com/.


The Company


Great Lakes Dredge & Dock Corporation is the largest provider of dredging services in the United States, which is complemented with a long history of performing significant international projects. In addition, Great Lakes is fully engaged in expanding its core business into the offshore energy industry. The Company employs experienced civil, ocean and mechanical engineering staff in its estimating, production and project management functions. In its over 135-year history, the Company has never failed to complete a marine project. Great Lakes owns and operates the largest and most diverse fleet in the U.S. dredging industry, comprised of approximately 200 specialized vessels. Great Lakes has a disciplined training program for engineers that ensures experienced-based performance as they advance through Company operations. The Company’s Incident-and Injury-Free® (IIF®) safety management program is integrated into all aspects of the Company’s culture. The Company’s commitment to the IIF® culture promotes a work environment where employee safety is paramount.


Cautionary Note Regarding Forward-Looking Statements


Certain statements in this press release may constitute “forward-looking” statements as defined in Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”), the Private Securities Litigation Reform Act of 1995 (the “PSLRA”) or in releases made by the Securities and Exchange Commission (the “SEC”), all as may be amended from time to time. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results, performance or achievements of Great Lakes and its subsidiaries, or industry results, to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements that are not historical fact are forward-looking statements. These cautionary statements are being made pursuant to the Exchange Act and the PSLRA with the intention of obtaining the benefits of the “safe harbor” provisions of such laws. Great Lakes cautions investors that any forward-looking statements made by Great Lakes are not guarantees or indicative of future events.

Although Great Lakes believes that its plans, intentions and expectations reflected in or suggested by such forward-looking statements are reasonable, actual results could differ materially from a projection or assumption in any forward-looking statements. Great Lakes’ future financial condition and results of operations, as well as any forward-looking statements, are subject to change and inherent risks and uncertainties. The forward-looking statements contained in this press release are made only as of the date hereof and Great Lakes does not have or undertake any obligation to update or revise any forward-looking statements whether as a result of new information, subsequent events or otherwise, unless otherwise required by law.


For further information contact:


Eric Birge
Vice President of Investor Relations
313-220-3053



Quest Resource Holding Corporation Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Added record eight new customers in 2024, reflecting strong value proposition

Refinanced debt in Q4, lowering interest expense by approximately $1 million annually,
reducing blended interest rate by approximately 150 basis points

Reducing headcount by 15% and SG&A by $3.0 million annually as result of ongoing operational efficiency gains and the anticipated exit of a non-core business line

Named Perry Moss CEO and Nick Ober SVP of Operations

THE COLONY, Texas, March 12, 2025 (GLOBE NEWSWIRE) — Quest Resource Holding Corporation (Nasdaq: QRHC) (“Quest” or the “Company”), a national leader in environmental waste and recycling services, today announced financial results for the fourth quarter and fiscal year ended December 31, 2024.


Fourth Quarter 2024 Financial Highlights

:

  • Revenue was $70.0 million, a 0.9% increase compared with the fourth quarter of 2023.
  • Gross profit was $10.7 million, a 6.7% decrease compared with the fourth quarter of 2023.
  • Gross margin was 15.3% of revenue compared with 16.6% during the fourth quarter of 2023.
  • GAAP net loss per diluted share attributable to common stockholders was $(0.46), compared with $(0.11) per diluted share during the fourth quarter of 2023.
  • Recognized a non-cash impairment loss of $5.5 million, or $(0.26) per diluted share, related to the anticipated sale of the tenant-direct mall portion of RWS.
  • Adjusted EBITDA was $1.7 million, compared with $3.5 million during the fourth quarter of 2023. Excluding a non-cash cost of revenue adjustment of approximately $1.0 million and a $0.5 million bad debt adjustment for receivables related to the business exit, adjusted EBITDA during the fourth quarter of 2024 would have been approximately $3.2 million.
  • Adjusted net loss per diluted share was $(0.09), compared with adjusted net income of $0.03 per diluted share during the fourth quarter of 2023.


Fiscal Year 2024 Financial Highlights:

  • Revenue was $288.5 million, a 0.1% increase compared with 2023.  
  • Gross profit was $50.0 million, a 0.1% decrease compared with 2023.  
  • Gross margin was 17.3% of revenue compared to 17.4% during 2023.
  • GAAP net loss per diluted share attributable to common stockholders was $(0.73), compared with $(0.36) during 2023.   
  • Adjusted EBITDA was $14.5 million, compared to $16.2 million during 2023.  
  • Adjusted net loss per diluted share was $(0.03), compared with adjusted net income of $0.15 per diluted share during 2023.  


During 2024, Quest achieved several milestones:

  • Successfully completed debt refinancing with existing lenders, reducing annual interest expense by approximately $1 million, while increasing credit line, improving terms, and extending maturities.
  • Secured eight new client wins expected to generate at least seven figures of annual revenue each, the greatest number of new client wins in one year in the history of the Company.
  • Secured five expansion service agreements with some of our largest existing clients, including one during the fourth quarter.
  • Added more than 1,200 vendors onto the Company’s service platform, adding to our ability to serve clients broadly.

“In 2024, we made meaningful progress executing against our key strategic priorities,” said Dan M. Friedberg, Chairman of the Company’s Board of Directors. “We added and are in the process of onboarding eight new customers and have expanded agreements with five of some of our largest customers, representing a record amount of new customer activity for the Company in a year. Further, the Company successfully refinanced its long-term debt with our existing lenders, reflecting their continued confidence in the business.”

Friedberg added, “Despite our success in growing the customer base and the substantial activity underway to solidify operations and efficiencies, we clearly recognize more needs to be done to address our execution issues. Our performance was affected by several factors: temporary cost increases from onboarding new clients, expenses for implementing our new vendor management system, client attrition, and weakness in our industrial client end markets. We believe the actions we have taken and the initiatives now underway will normalize operations in the coming quarters and help position Quest to drive long-term results.”


Specific actions include:

  • Announced today in a separate news release that Perry Moss has been named Chief Executive Officer. Moss previously served as Quest’s Chief Revenue Officer, and previously held senior leadership roles at Rubicon Technologies, Inc., Oakleaf Holdings, and Smurfit-Stone’s Waste Reduction Services’ business unit. Ray Hatch is retiring as CEO and will remain on the Board of Directors.
  • Announced that Nick Ober has joined the Company as Senior Vice President of Operations. Ober most recently served as Vice President of Freight Brokerage Solutions & Strategy for RXO, Inc., the tech-enabled brokered transportation platform, a spin-off from XPO, Inc., where he led carrier operations for a $3 billion asset-light business unit. He also has deep industry experience, having been Director of Operations for a $400 million region for Republic Services, Inc. Ober will work closely with Dave Sweitzer, Quest’s Chief Operating Officer, will oversee the Vendor Management Group, and will also lead the newly created Operations Excellence Initiative.
  • Entered into an understanding to sell the non-core tenant-direct mall portion of RWS, the Company’s mall business subject to execution of a definitive agreement.
  • Implementing a reduction of headcount by 15%, which, combined with the partial sale of RWS and ongoing efficiency improvement gains, should reduce SG&A by approximately $3.0 million on an annualized basis.
  • Established an Operational Excellence Initiative, which will benchmark, measure, and target improvement levels across the entire workflow. This fully integrated effort will look to drive process improvements, enhance employee experience, increase customer value-added, expand margins and accelerate the achievement of scale benefits.

Perry Moss, Quest’s Chief Executive Officer, stated, “I believe strongly in Quest’s value proposition and in the power of our platform. We have a tremendous roster of clients, and a highly capable organization focused on generating value for our stakeholders. Importantly, we have a robust pipeline of potential new business, and we expect to continue to deepen client relationships, add valuable services and solutions, invest in our business and people, and improve profitability.”

Mr. Friedberg concluded, “The board and management team are committed to driving change and enhancing shareholder value. We have a strong platform and are focused on operational excellence. We have implemented performance-focused actions and will continue pursuing initiatives to drive value for all stakeholders.”


Fourth Quarter and Fiscal Year 2024 Earnings Conference Call and Webcast

Quest will conduct a conference call Wednesday, March 12, 2025, at 5:00 PM ET, to review the financial results for the fourth quarter and year ended December 31, 2024. Investors interested in participating on the live call can dial 1-800-717-1738 or 1-646-307-1865. The conference call, which may include forward-looking statements, is also being webcast and is available via the investor relations section of Quest’s website at https://investors.qrhc.com/investors. A replay of the webcast will be archived on Quest’s investor relations website for 90 days.


About Quest Resource Holding Corporation


Quest is a national provider of waste and recycling services that enable larger businesses to excel in achieving their environmental and sustainability goals and responsibilities. Quest delivers focused expertise across multiple industry sectors to build single-source, client-specific solutions that generate quantifiable business and sustainability results. Addressing a wide variety of waste streams and recyclables, Quest provides information and data that tracks and reports the environmental results of Quest’s services, gives actionable data to improve business operations, and enables Quest’s clients to excel in their business and sustainability responsibilities. For more information, visit www.qrhc.com.


Reconciliation of U.S. GAAP to Non-GAAP Financial Measures

In this press release, non-GAAP financial measures, “Adjusted EBITDA,” and “Adjusted Net Income (Loss)” are presented. From time-to-time, Quest considers and uses these supplemental measures of operating performance in order to provide an improved understanding of underlying performance trends. Quest believes it is useful to review, as applicable, both (1) GAAP measures that include (i) depreciation and amortization, (ii) interest expense, (iii) stock-based compensation expense, (iv) income tax expense, and (v) certain other adjustments, and (2) non-GAAP measures that exclude such items. Quest presents these non-GAAP measures because it considers them an important supplemental measure of Quest’s performance. Quest’s definition of these adjusted financial measures may differ from similarly named measures used by others. Quest believes these measures facilitate operating performance comparisons from period to period by eliminating potential differences caused by the existence and timing of certain expense items that would not otherwise be apparent on a GAAP basis. These non-GAAP measures have limitations as an analytical tool and should not be considered in isolation or as a substitute for the Company’s GAAP measures. (See attached tables “Reconciliation of Net Loss to Adjusted EBITDA” and “Adjusted Net Income (Loss) Per Share”).


Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, which provides a “safe harbor” for such statements in certain circumstances. The forward-looking statements include, but are not limited to, our expectation that we will continue to deepen client relationships, add valuable services and solutions, and invest in our business and people, resulting in long-term, continuously expanding client relationships; and our belief that the implementation of a reduction of headcount by 15%, combined with the partial sale of RWS and ongoing efficiency improvement gains, should reduce SG&A by approximately $3.0 million on an annualized basis. Actual events or results could differ materially from those discussed in the forward-looking statements as a result of various factors, including, but not limited to, competition in the environmental services industry, the impact of the current economic environment, interruptions to supply chains, commodity price fluctuations, and extended shut down of businesses, and other factors discussed in greater detail in our filings with the Securities and Exchange Commission (“SEC”), including our Annual Report on Form 10-K for the year ended December 31, 2024. You are cautioned not to place undue reliance on such statements and to consult our SEC filings for additional risks and uncertainties that may apply to our business and the ownership of our securities. Our forward-looking statements are presented as of the date made, and we disclaim any duty to update such statements unless required by law to do so.

Investor Relations Contact:

Three Part Advisors, LLC
Joe Noyons
817.778.8424

   Financial Tables Follow  

Quest Resource Holding Corporation and Subsidiaries

STATEMENTS OF OPERATIONS

(In thousands, except per share amounts)
                             
    Three Months Ended


      Year Ended


 
    December 31,


      December 31,


 
    2024       2023     2024
  2023  
    (Unaudited)      
Revenue $ 69,970     $ 69,342     $ 288,532     $ 288,378  
Cost of revenue   59,243       57,842       238,537       238,313  
Gross profit   10,727       11,500       49,995       50,065  
Selling, general, and administrative   10,086       9,419       39,543       37,669  
Depreciation and amortization   2,307       2,352       9,401       9,571  
Impairment loss   5,511             5,511        
Total operating expenses   17,904       11,771       54,455       47,240  
Operating income (loss)   (7,177 )     (271 )     (4,460 )     2,825  
Interest expense   (2,505 )     (2,322 )     (10,312 )     (9,729 )
Loss before taxes   (9,682 )     (2,593 )     (14,772 )     (6,904 )
Income tax expense (benefit)   (174 )     (263 )    

291

     

387

 
Net loss $ (9,508 )   $ (2,330 )   $ (15,063 )   $ (7,291 )
                             
                             
Net loss applicable to common stockholders $ (9,508 )   $ (2,330 )   $ (15,063 )   $ (7,291 )
Net loss per common share:                            
Basic $ (0.46 )   $ (0.11 )   $ (0.73 )   $ (0.36 )
Diluted $ (0.46 )   $ (0.11 )   $ (0.73 )   $ (0.36 )
                               
Weighted average number of common shares outstanding:                              
Basic   20,837       20,264       20,617       20,123  
Diluted   20,837       20,264       20,617       20,123  
                             

RECONCILIATION OF NET LOSS TO ADJUSTED EBITDA

(Unaudited)
(In thousands)
                               
  Three Months Ended


    Year Ended
    December 31,       December 31,
    2024       2023       2024       2023  
Net loss $ (9,508 )   $ (2,330 )   $ (15,063 )   $ (7,291 )
Depreciation and amortization   2,558       2,462       10,272       9,948  
Interest expense   2,505       2,322       10,312       9,729  
Stock-based compensation expense   272       362       1,563       1,312  
Acquisition, integration, and related costs   21       598       112       1,624  
Impairment loss   5,511             5,511        
Other adjustments   491       329       1,471       501  
Income tax expense (benefit)   (174 )     (263 )     291       387  
Adjusted EBITDA $ 1,676     $ 3,480     $ 14,469     $ 16,210  
                               

ADJUSTED NET INCOME (LOSS) PER SHARE
(Unaudited)
(In thousands)
             
    Three Months Ended     Year Ended  
    December 31,     December 31,  
    2024       2023       2024       2023  
Reported net loss(1) $ (9,508 )   $ (2,330 )   $ (15,063 )   $ (7,291 )
Amortization of intangibles(2)   2,137       2,196       8,787       8,864  
Acquisition, integration, and related costs(3)   21       598       112       1,624  
Impairment loss   5,511             5,511        
Other adjustments(4)         280             205  
Adjusted net income (loss) $ (1,839 )   $ 744     $ (653 )   $ 3,402  
                               
Diluted earnings (loss) per share:                              
Reported net loss $ (0.46 )   $ (0.11 )   $ (0.73 )   $ (0.36 )
Adjusted net income (loss) $ (0.09 )   $ 0.03     $ (0.03 )   $ 0.15  
                               
Weighted average number of common shares outstanding: Diluted(5)   20,837       22,502       20,617       22,362  
                               
(1)   Applicable to common stockholders
(2)   Reflects the elimination of non-cash amortization of acquisition-related intangible assets
(3)   Reflects the add back of acquisition/integration related transaction costs
(4)   Reflects adjustments to earn-out fair value
(5)   Reflects adjustment for dilution when adjusted net income is positive              
 
                               

BALANCE SHEETS

(In thousands, except per share amounts)
             
  December 31,     December 31,
  2024     2023  
             
ASSETS            
Current assets:            
Cash and cash equivalents $ 396     $ 324  
Accounts receivable, less allowance for doubtful accounts of $831
and $1,582 as of December 31, 2024 and 2023, respectively
  62,252       58,147  
Prepaid expenses and other current assets   2,601       2,142  
Assets held for sale   9,890        
Total current assets   75,139       60,613  
             
Goodwill   81,065       85,828  
Intangible assets, net   12,946       26,052  
Property and equipment, net, and other assets   6,495       4,626  
Total assets $ 175,645     $ 177,119  
             
LIABILITIES AND STOCKHOLDERS’ EQUITY            
Current liabilities:            
Accounts payable and accrued liabilities $ 39,899     $ 41,296  
Other current liabilities   1,001       2,470  
Current portion of notes payable   1,651       1,159  
Liabilities held for sale   1,840        
Total current liabilities   44,391       44,925  
             
Notes payable, net   76,265       64,638  
Other long-term liabilities   833       1,275  
Total liabilities   121,489       110,838  
             
Commitments and contingencies            
             
Stockholders’ equity:            
Preferred stock, $0.001 par value, 10,000 shares authorized, no
shares issued or outstanding as of December 31, 2024 and 2023
         
Common stock, $0.001 par value, 200,000 shares authorized,
20,606 and 20,161 shares issued and outstanding as
of December 31, 2024 and 2023, respectively
  21       20  
Additional paid-in capital   179,246       176,309  
Accumulated deficit   (125,111 )     (110,048 )
Total stockholders’ equity   54,156       66,281  
Total liabilities and stockholders’ equity $ 175,645     $ 177,119  
               



ContextLogic Inc. Reports Fourth-Quarter and Fiscal Year 2024 Financial Results

OAKLAND, Calif., March 12, 2025 (GLOBE NEWSWIRE) — ContextLogic Inc. (Nasdaq: LOGC) (“ContextLogic,” the “Company,” “we” or “our”) today reported its financial results for the quarter and fiscal year ended December 31, 2024.

Company Update

During 2024, management took several significant steps in the evolution of the Company’s business. These included, first, the sale of the Wish platform and its associated operations; second, streamlining the Company’s operations; and most recently, on March 11, 2025, the Company announced the initial closing of the investment by BC Partners of $75 million in convertible preferred units in a subsidiary of ContextLogic. This investment, along with the approximately $66 million of cash and cash equivalents and approximately $83 million in marketable securities on the Company’s balance sheet, provides the Company with approximately $225 million in liquidity available for investment in its business, with the potential for an additional $75 million in convertible preferred units to be issued in connection with an acquisition.

Fourth-Quarter Fiscal 2024 Financial Highlights

  • Net Loss: Net Loss was $2 million, compared to a net loss of $68 million in the fourth quarter of fiscal 2023
  • As of December 31, 2024, the Company had $66 million in cash and cash equivalents, $83 million in marketable securities and $7 million in prepaid expenses and other current assets primarily made up of restricted cash. The Company had total liabilities of $5 million.

ContextLogic will host a financial results and strategic update conference call at 5pm EDT on March 12th. The live conference call may be accessed by registering here. The associated strategic investment presentation deck can be found here on the ContextLogic Investor Relations website.

Company Outlook

The Company continues to streamline its administrative structure as it focuses on achieving its value maximization strategy both organically and through accretive acquisitions. The recent investment by BC Partners was an important milestone in that effort. Management and the Board of Directors continue to focus on identifying, evaluating and potentially executing strategic opportunities for the benefit of ContextLogic and its stockholders.

During the three months ended December 31, 2024, the Company incurred $4 million of general and administrative expenses primarily related to legal expenses, employee expenses, and other professional services. At the conclusion of the three months ended December 31, 2024, ContextLogic had eight full-time employees.

The Company earned interest income of $2 million during the three months ended December 31, 2024. With the Company’s marketable securities and cash and cash equivalents primarily invested in U.S. government instruments.

“We are very pleased with how far the Company has come and look forward to working with Ted Goldthorpe and Mark Ward, our new directors from the world class team at BC Partners, as we embark on the next stage of ContextLogic’s evolution,” said Rishi Bajaj, Chief Executive Officer and Director.

About Contextlogic Inc

ContextLogic Inc. is a publicly traded company currently seeking to develop and grow a de novo business and finance potential future bolt-on acquisitions of assets or businesses that are complementary to its operations. For more information on ContextLogic, please visit ir.contextlogicinc.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact could be deemed forward-looking, including, but not limited to, statements regarding ContextLogic’s financial outlook, the strategic alternatives considered by our Board of Directors, including the decisions taken thereto and alternatives for the use of the cash or cash equivalents, and other quotes of management. In some cases, forward-looking statements can be identified by terms such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “foresees,” “forecasts,” “guidance,” “intends” “goals,” “may,” “might,” “outlook,” “plans,” “potential,” “predicts,” “projects,” “seeks,” “should,” “targets,” “will,” “would” or similar expressions and the negatives of those terms. These forward-looking statements are subject to risks, uncertainties, and assumptions. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. Important factors, risks and uncertainties that could cause actual results to differ materially from those forward-looking statements include but are not limited to: the strategic alternatives considered by our Board of Directors, including the decisions taken thereto; our lack of operating revenues after the sale of substantially all of our assets in April 2024; our prior history of losses; our intention not to liquidate and distribute sale proceeds to our stockholders after the sale of substantially all of our assets; our continuation as a publicly-traded and reporting company after the sale of substantially all of our assets; our ability to utilize our net operating loss carryforwards and other tax attributes; risks related to any future acquisition of a business or assets; risks if we fail to develop a viable future business plan or fail to acquire a business or assets and generate revenues; risks if we engage in a business combination that has adverse tax consequences to us or our stockholders; risks if we pursue a business combination with a privately-held target; our retention of certain liabilities relating to the assets we sold and our indemnification obligations under the sale agreement for those assets; risks if we fail to make, integrate or maintain future acquisitions and investments; risks associated with a failure to maintain effective disclosure controls and internal control over financial reporting; currently pending or future litigation; changes to laws and regulations that could affect our business or ability to pursue chosen strategic alternatives; risks if we are deemed to be an investment company under the Investment Company Act of 1940; our management strategies and plans, competitive position, business environment, potential growth strategies and opportunities; our continued listing on Nasdaq; impact of future issuances of our common stock or rights to purchase our common stock; impact of our Tax Benefits Preservation Plan on our stock performance; volatility in our stock price; impact of anti-takeover provisions in our charter documents, in our Tax Benefits Preservation Plan and under Delaware law; our possible or assumed future financial performance; our future liquidity and operating expenditures; our financial condition and results of operations; competitive changes in the marketplace; our expected tax rate; the effect of changes in or the application of new or revised tax laws; the effect of new accounting pronouncements; and the other important factors discussed in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Further information on these and additional risks that could affect ContextLogic’s results is included in its filings with the Securities and Exchange Commission (“SEC”), including the Quarterly Report on Form 10-Q for the periods ended June 30, 2024 and September 30, 2024 and other reports that ContextLogic files with the SEC from time to time, which could cause actual results to vary from expectations. Any forward-looking statement made by ContextLogic in this news release speaks only as of the day on which ContextLogic makes it. ContextLogic assumes no obligation to, and does not currently intend to, update any such forward-looking statements after the date of this release.

ContextLogic Inc.

Condensed Consolidated Balance Sheets

(in millions)

(unaudited)
 
    As of December 31,     As of December 31,  
    2024     2023  
Assets            
Current assets:            
Cash and cash equivalents   $ 66     $ 238  
Marketable securities     83       144  
Funds receivable           7  
Prepaid expenses and other current assets     7       21  
Total current assets     156       410  
Property and equipment, net           4  
Right-of-use assets           5  
Other assets           4  
Total assets   $ 156     $ 423  
Liabilities and Stockholders’ Equity            
Current liabilities:            
Accounts payable   $     $ 30  
Merchants payable           74  
Refunds liability           2  
Accrued liabilities     5       90  
Total current liabilities     5       196  
Lease liabilities, non-current           6  
Other liabilities, non-current           4  
Total liabilities     5       206  
Stockholders’ equity     151       217  
Total liabilities and stockholders’ equity   $ 156     $ 423  

ContextLogic Inc.

Condensed Consolidated Statements of Operations

(in millions, except per share data)

(unaudited)
 
  Three Months Ended     Year Ended  
  December 31,     December 31,  
  2024     2023     2024     2023  
Revenue $     $ 53     $ 43     $ 287  
Cost of revenue         44       36       228  
Gross profit         9       7       59  
Operating expenses:                      
Sales and marketing         32       18       143  
Product development         25       26       152  
General and administrative   4       24       42       92  
Total operating expenses   4       81       86       387  
Loss from operations   (4 )     (72 )     (79 )     (328 )
Other income, net:                      
Interest and other income, net   2       3       6       16  
Gain on Asset Sale               4        
Loss before provision for (benefit from) income taxes   (2 )     (69 )     (69 )     (312 )
Provision for (benefit from) income taxes         (1 )     6       5  
Net loss $ (2 )   $ (68 )   $ (75 )   $ (317 )
Net loss per share, basic and diluted $ (0.08 )   $ (2.82 )   $ (2.92 )   $ (13.36 )
Weighted-average shares used in computing net loss per share, basic and diluted   26,292       24,119       25,690       23,732  

ContextLogic Inc.

Condensed Consolidated Statements of Cash Flows

(in millions)

(unaudited)
 
  Three Months Ended     Year Ended  
  December 31,     December 31,  
  2024     2023     2024     2023  
Cash flows from operating activities:                      
Net loss $ (2 )   $ (68 )   $ (75 )   $ (317 )
Adjustments to reconcile net loss to net cash used in operating activities:                      
Depreciation and amortization         1       1       4  
Noncash lease expense               1       3  
Impairment of lease assets and property and equipment                     1  
Stock-based compensation expense         10       12       64  
Net (accretion) of discounts and premiums on marketable securities   (1 )     (1 )     (4 )     (7 )
Gain on Asset Sale               (4 )      
Other                     1  
Changes in operating assets and liabilities:                      
Funds receivable         (2 )           6  
Prepaid expenses, other current and noncurrent assets   1             1       16  
Accounts payable         (5 )     (15 )     (22 )
Merchants payable         (3 )     (8 )     (46 )
Accrued and refund liabilities         (6 )     (7 )     (38 )
Lease liabilities         (2 )     (2 )     (7 )
Other current and noncurrent liabilities         1       6       1  
Net cash used in operating activities   (2 )     (75 )     (94 )     (341 )
Cash flows from investing activities:                      
Purchases of property and equipment and development of internal-use software                     (3 )
Cash disposed on Asset Sale, net of proceeds               (133 )      
Purchases of marketable securities   (48 )     (74 )     (168 )     (313 )
Sales of marketable securities               5        
Maturities of marketable securities   83       73       228       390  
Net cash provided by (used) in investing activities   35       (1 )     (68 )     74  
Cash flows from financing activities:                      
Payments of taxes related to RSU settlement and cashless exercise of stock options               (1 )     (5 )
Net cash used in financing activities               (1 )     (5 )
Foreign currency effects on cash, cash equivalents and restricted cash         4       (2 )     (3 )
Net increase (decrease) in cash, cash equivalents and restricted cash   33       (72 )     (165 )     (275 )
Cash, cash equivalents and restricted cash at beginning of period   40       310       238       513  
Cash, cash equivalents and restricted cash at end of period $ 73     $ 238     $ 73     $ 238  
Reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets:                      
Cash and cash equivalents $ 66     $ 238     $ 66     $ 238  
Restricted cash included in prepaid and other current assets in the consolidated balance sheets   7             7        
Total cash, cash equivalents and restricted cash $ 73     $ 238     $ 73     $ 238  
Supplemental cash flow disclosures:                      
Cash paid for income taxes, net of refunds $     $     $     $ 1  



Contacts

Investor Relations:

Lucy Simon, CLI
[email protected]